🕒 Last update: loading…

Stock Vor Biopharma Inc. VOR

Vor Biopharma Inc. — Investlytic score 0/5 on the five criteria.

-
-
0/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 0/5 criteria met.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2021 → 2022: -42.77%

Price change 2022 → 2023: -66.17%

Price change 2023 → 2024: -50.67%

Price change 2024 → 2025: -41.08%

Price change 2025 → 2026: 38.07%

Price change 2026 (year to date): 55.15%

Financial growth

Revenue CAGR (8 years): N/A

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 3000000.00

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -5.91

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 28.05% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Vor Biopharma Inc.–––🔒
Vetoquinol S.A.16.60.03+4.2 %–
DocMorris AG–0.71+5.7 %–
Gerresheimer AG31.71.48+5.6 %–
Nutex Health, Inc.6.91.07+54.6 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Accounts and financial health

Balance sheet and cash flow published by Vor Biopharma Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
6.82
safe zone (above 2.99)
Piotroski Score
3 / 9
0 to 3: fragile accounts
DCF Value
39.40 USD
DCF above share price · share price 18.29 USD, gap +115.4 %
Net Debt / EBITDA
-0.06 x
net cash
Fiscal year20212022202320242025
Cash and investments207 m230 m137 m91.9 m455 m
Total Debt18.0 m38.9 m35.7 m31.8 m3.0 m
Net Debt-102 m-18.8 m4.3 m-50.1 m-393 m
Equity216 m251 m151 m96.7 m-164 m
Total assets243 m299 m210 m143 m464 m
Operating cash flow-69.1 m-85.1 m-100 m-99.7 m-143 m
Investments (capex)3.9 m8.5 m1.1 m229,000941,000
Free cash-flow-73.0 m-93.6 m-101 m-99.9 m-144 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)0.06 x
Price / book value-8.06 x
Return on Equity (ROE)-830.4 %
Return on Invested Capital (ROIC)-38.5 %
Net margin0.0 %
Debt / equity-0.02 x
Current ratio13.50 x
Free cash-flow yield-12.0 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

Vor Biopharma Inc. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Vor Biopharma Inc.1.1 bnn/a0.0 %
Sana Biotechnology, Inc. SANA605 mn/a0.0 %
CRISPR Therapeutics AG CRSP4.1 bnn/a-16,569.8 %
Rocket Pharmaceuticals, Inc. RCKT257 mn/a0.0 %
Nkarta, Inc. NKTX85.2 mn/a0.0 %
Fate Therapeutics, Inc. FATE149 mn/a-2,051.1 %
Century Therapeutics, Inc. IPSC300 mn/a-8.8 %
Autolus Therapeutics plc AUTL311 mn/a-381.4 %
Editas Medicine, Inc. EDIT335 mn/a-395.0 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Vor Biopharma Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
13 analysts

Breakdown of ratings

strong buy 0buy 10hold 3sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 2 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Vor Biopharma Inc.

Free float
65.8 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 05/02/2021
ISIN code
US9290332074
Workforce
159
full-time employees
Chief executive
Robert Ang MBBS

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Vor Biopharma Inc.

What is the Vor Biopharma Inc. share price?

Latest recorded price: 19.42 USD on 13/11/2026, for a market cap of 1.1 bn USD.

What do analysts say about Vor Biopharma Inc.?

Out of 13 analysts: 10 buy or strong buy, 3 hold, 0 sell or strong sell.

Is Vor Biopharma Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US9290332074).

How many employees does Vor Biopharma Inc. have?

159 full-time employees according to the latest published profile.

Who runs Vor Biopharma Inc.?

Robert Ang MBBS is the company's chief executive.

07

Similar stocks